title: BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?
abstract: Prosurvival protein BCL-2 is overexpressed in estrogen receptor positive (ER(+)) breast cancer. In this issue of Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the response of xenografts from primary ER(+) breast tumors to endocrine therapy and reduces tamoxifen-induced endometrial hyperplasia, a strategy with potential clinical applicability.
authors.affiliation: Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. lesley-ann.martin@icr.ac.uk
authors.forename: Lesley-Ann
authors.initials: LA
authors.lastname: Martin
authors.forename: Mitch
authors.initials: M
authors.lastname: Dowsett
mesh_terms: D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009596:Nitrophenols / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000502:physiology; D011960:Receptors, Estrogen / Q000032:analysis* / Q000502:physiology; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: C501332:ABT-737; D001713:Biphenyl Compounds; D009596:Nitrophenols; D010879:Piperazines; D019253:Proto-Oncogene Proteins c-bcl-2; D011960:Receptors, Estrogen; D013449:Sulfonamides